why choose us

Clinical Trials Search

Showing 7,950 of 132,085 result(s)
Assessment of Measurement Variability Across Automated Biometry Devices

Status: Completed

Condition: Myopia

Interventions: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Date: 2023-09-14

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Status: NOT_YET_RECRUITING

Condition: Chronic Graft Versus Host Disease

Interventions: 200mg PO QD x 24 cycles (28-day cycle)

Date: 2023-09-14

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R;M) HPV Negative Head and Neck Squamous Cell Carcinoma

Status: Completed

Condition: Metastatic Head-and-neck Squamous-cell Carcinoma

Interventions: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

Date: 2023-09-14

Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI;US Image Fusion for Guidance

Status: Completed

Condition: Prostate Cancer

Interventions: Removal of cancerous tissue through the direct application of laser energy

Date: 2023-09-14

RCT of Intensive Multi-Couple Therapy for PTSD Versus Relationship Education in Military Couples

Status: Completed

Condition: Posttraumatic Stress Disorder

Interventions: Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.
Couples are provided with psychoe

Date: 2023-09-14

Improving Short Course Treatment for Common Pediatric Infections

Status: COMPLETED

Condition: Community-acquired Pneumonia

Interventions: Clinicians within practices assigned to the Education;Feedback group received a personal email from one of the authors at the outset of the proje

Date: 2023-09-14

The Effect of State and Trait Anxiety on Pain-pressure Threshold

Status: COMPLETED

Condition: Pain

Interventions: No intervention

Date: 2023-09-14

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Status: Completed

Condition: Solid Tumor, Adult

Interventions:

Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of each 21-day cycle.

Dose Escalation Combination Phase: C

Date: 2023-09-14

Accommodative Behaviors in Multifocal Contact Lenses

Status: Completed

Condition: Accommodation Disorder

Interventions: Coopervision Biofinity Multifocal Lens

Date: 2023-09-14